David A. Siegel Crispr Therapeutics Ag Transaction History

Two Sigma Advisers, LP

$41.3 Billion
Q4 2024

A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Crispr Therapeutics Ag stock. As of the latest transaction made, Two Sigma Advisers, LP holds 84,800 shares of CRSP stock, worth $3.72 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

84,800

Previous 56,400 50.35%

Holding current value

$3.72 Million

Previous $2.65 Million 25.92%

% of portfolio

0.01%

Previous 0.01%

20 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	BUY	$38.65 - $55.15 $1.1 Million - $1.57 Million	28,400 Added 50.35%	84,800 $3.34 Million
Q3 2024 Nov 14, 2024	BUY	$44.62 - $62.75 $2.52 Million - $3.54 Million	56,400 New	56,400 $2.65 Million
Q3 2023 Nov 14, 2023	SELL	$45.39 - $59.0 $349,503 - $454,300	-7,700 Reduced 44.51%	9,600 $435,000
Q2 2023 Aug 14, 2023	BUY	$43.47 - $67.77 $752,031 - $1.17 Million	17,300 New	17,300 $971,000
Q4 2021 Feb 14, 2022	SELL	$70.09 - $111.29 $15.5 Million - $24.6 Million	-220,600 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$110.2 - $156.64 $75.4 Million - $107 Million	-684,200 Reduced 75.62%	220,600 $24.7 Million
Q2 2021 Aug 16, 2021	SELL	$100.84 - $161.89 $12.4 Million - $19.9 Million	-122,900 Reduced 11.96%	904,800 $146 Million
Q1 2021 May 17, 2021	BUY	$110.72 - $210.04 $74 Million - $140 Million	668,000 Added 185.71%	1,027,700 $125 Million
Q4 2020 Feb 16, 2021	BUY	$79.67 - $173.23 $2.96 Million - $6.44 Million	37,200 Added 11.53%	359,700 $55.1 Million
Q3 2020 Nov 16, 2020	BUY	$78.5 - $100.64 $6.97 Million - $8.94 Million	88,800 Added 38.0%	322,500 $27 Million
Q2 2020 Aug 14, 2020	BUY	$38.5 - $76.05 $261,800 - $517,140	6,800 Added 3.0%	233,700 $17.2 Million
Q1 2020 May 15, 2020	SELL	$33.68 - $62.53 $2.05 Million - $3.8 Million	-60,800 Reduced 21.13%	226,900 $9.62 Million
Q4 2019 Feb 14, 2020	BUY	$36.68 - $73.13 $8.45 Million - $16.8 Million	230,400 Added 402.09%	287,700 $17.5 Million
Q3 2019 Nov 14, 2019	SELL	$40.99 - $52.56 $2.25 Million - $2.88 Million	-54,800 Reduced 48.88%	57,300 $2.35 Million
Q2 2019 Aug 14, 2019	SELL	$35.45 - $48.2 $4.51 Million - $6.14 Million	-127,300 Reduced 53.17%	112,100 $5.28 Million
Q1 2019 May 15, 2019	SELL	$28.02 - $40.87 $6.55 Million - $9.55 Million	-233,700 Reduced 49.4%	239,400 $8.55 Million
Q4 2018 Feb 14, 2019	BUY	$22.73 - $42.34 $1.36 Million - $2.54 Million	60,000 Added 14.52%	473,100 $13.5 Million
Q3 2018 Nov 14, 2018	BUY	$44.35 - $65.71 $1.97 Million - $2.92 Million	44,500 Added 12.07%	413,100 $18.3 Million
Q2 2018 Aug 14, 2018	BUY	$42.62 - $73.59 $14.2 Million - $24.6 Million	334,200 Added 971.51%	368,600 $21.7 Million
Q1 2018 May 15, 2018	BUY	$23.52 - $58.17 $809,088 - $2 Million	34,400 New	34,400 $1.57 Million

Others Institutions Holding CRSP

# of Institutions

487

Shares Held

64.1M

Call Options Held

1.64M

Put Options Held

1.93M

View Full List

About CRISPR Therapeutics AG

Ticker CRSP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 78,009,296
Market Cap $3.42B
Description
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....

More about CRSP

Track David A. Siegel's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.

Account